A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
Trial details
- Registry ID
- NCT06270836
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as KSI-301; Tarcocimab tedromer
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)NCT06270836 | KOD | Phase 3 | Completed | 2026-02-13Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |